Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
AssigneesDignity Health, The Translational Genomics Research Institute
InventorsShwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
Claims10
A method of treating a cancer in a subject, comprising:
- obtaining a sample from the subject;
- assaying the sample to determine the expression levels of Base Excision Repair (BER) pathway markers comprising Apex 1, Apex 2, and MPG relative to levels found in a non-tumor cell,
- wherein a low level of Apex 1, a low level of Apex 2, and a high level of MPG relative to levels found in a non-tumor cell is indicative of responsiveness to a cancer therapeutic;
- and
- treating the subject when a low level of Apex 1, a low level of Apex 2, and a high level of MPG is found,
- wherein the low level of Apex 1 is between 1.300 and 3.600, the low level of Apex 2 is between 0 and 0.400 and the high level of MPG is between 1.200 and 2.800.
Dependencies are inferred from the claim text.